KAPA
MaterialsKairos Pharma Ltd
$0.55-0.00 (-0.02%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving KAPA Today?
No stock-specific AI insight has been generated for KAPA yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$12M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume93K
Avg Volume (10D)—
Shares Outstanding21.4M
KAPA News
20 articles- KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law FirmGlobeNewswire Inc.·Apr 29, 2026
- Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare InnovationYahoo Finance·Apr 15, 2026
- Kairos Pharma signs deal for Celyn Therapeutics’ CL-273Pharmaceutical-technology·Mar 3, 2026
- Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn TherapeuticsYahoo Finance·Mar 2, 2026
- Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn TherapeuticsYahoo Finance·Feb 26, 2026
- Kairos Pharma to Present at 3rd Annual DealFlow Discovery ConferenceYahoo Finance·Jan 20, 2026
- Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate CancerYahoo Finance·Dec 17, 2025
- Kairos Pharma Provides Shareholder UpdateYahoo Finance·Nov 4, 2025
- Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) MeetingYahoo Finance·Oct 20, 2025
- Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025Yahoo Finance·Oct 7, 2025
- Kairos Pharma reports positive data from Phase II prostate cancer treatment trialClinicaltrialsarena·Sep 19, 2025
- Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One YearYahoo Finance·Sep 18, 2025
- Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate CancerYahoo Finance·Sep 11, 2025
- Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025Yahoo Finance·Sep 3, 2025
- Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 2, 2025
- CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy TimelineYahoo Finance·Jul 28, 2025
- Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025Yahoo Finance·Jul 16, 2025
- Top Midday GainersYahoo Finance·Jul 15, 2025
- Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate CancerYahoo Finance·Jul 15, 2025
- Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual MeetingYahoo Finance·Jun 3, 2025
All 20 articles loaded
Price Data
Open$0.57
Previous Close$0.56
Day High$0.57
Day Low$0.56
52 Week High—
52 Week Low—
Fundamentals
Market Cap$12M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume93K
Avg Volume (10D)—
Shares Outstanding21.4M
About Kairos Pharma Ltd
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeAMEX
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—